Pamela Kryskow's guest appearances

Pamela Kryskow

Psychedelics Today

The Psychedelic Podcast

Comes A Time

Brom Podcast

Good Dudes Grow

The Metaphysical Mentor Show with Michael Philpott 

Psychedelic Diaries

Leadershipedelics

OwlTail

Paul Stamets

In this episode Oteil and Mike dive deep into the transformative power of psychedelics with renowned mycologist Paul Stamets and psychotherapist Pamela Kryskow. They explore the concept of ancestral trauma, discussing how understanding our family's history can impact our own lives. The conversation delves into the potential for psychedelic therapies to heal first responders, addressing the traumas that led them to their professions. From the benefits of psilocybin mushrooms in reducing crime and addiction to the integration of psychedelics into end-of-life care, this episode offers an enlightening exploration of the profound impact of these medicines on our well-being. Join the hosts as they discuss the latest research and ongoing initiatives pushing for the freedom of consciousness and the recognition of the therapeutic potential of psychedelics.The Comes A Time Podcast and content posted by Comes A Time is presented solely for general informational, educational, and entertainment purposes. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. It is not intended as a substitute for the advice of a physician, professional coach, psychotherapist, or other qualified professional, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical or mental health condition they may have and should seek the assistance of their healthcare professionals for any such conditions.﻿https://linktr.ee/comesatimepodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Oteil and Mike dive deep into the transformative power of psychedelics with renowned mycologist Paul Stamets and psychotherapist Pamela Kryskow. They explore the concept of ancestral trauma, discussing how understanding our family's history can impact our own lives. The conversation delves into the potential for psychedelic therapies to heal first responders, addressing the traumas that led them to their professions. From the benefits of psilocybin mushrooms in reducing crime and addiction to the integration of psychedelics into end-of-life care, this episode offers an enlightening exploration of the profound impact of these medicines on our well-being. Join the hosts as they discuss the latest research and ongoing initiatives pushing for the freedom of consciousness and the recognition of the therapeutic potential of psychedelics.The Comes A Time Podcast and content posted by Comes A Time is presented solely for general informational, educational, and entertainment purposes. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. It is not intended as a substitute for the advice of a physician, professional coach, psychotherapist, or other qualified professional, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical or mental health condition they may have and should seek the assistance of their healthcare professionals for any such conditions.﻿<a href="https://linktr.ee/comesatimepodcast" rel="nofollow" target="_blank">https://linktr.ee/comesatimepodcast</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Paul Stamets & Pamela Kryskow, M.D

Devon Christie

In this episode, Joe interviews Dr. Devon Christie: Senior Lead of Psychedelic Programs at Numinus, educator at CIIS and Vital, and MAPS-certified MDMA therapist; and Dr. Pamela Kryskow, MD: founding board member of the Psychedelic Association of Canada and Medical Lead of the nonprofit, Roots To Thrive. Christie and Kryskow recently co-authored one of the first papers looking at MDMA for chronic pain, “MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder,” which came about after they received access to MAPS’ Phase 2 data from a lead-in PTSD study and noticed significant improvements in pain measurements – something the study was not looking for at all. They’re looking into where chronic pain fits within the frameworks of Western medicine and psychedelic-assisted therapy, and discuss the many reasons why MDMA should be tremendously helpful for chronic pain and other conditions that fall under the large umbrella of central sensitivity syndromes and nociplastic pain. They are currently working on a new study following the MAPS protocol that will research MDMA-assisted psychotherapy specifically for people with fibromyalgia, which some believe might be physicalized PTSD. If you’d like to contribute a tax-deductible donation, visit giving.viu.ca, select “other” from the dropdown, and type in “MDMA for Fibromyalgia.” They talk about how research trials focus too much on the molecule while ignoring what the patient is saying; how a large percentage of physicians and patients don’t at all like the psychometrics used in measuring data; how physicians regularly use expectancy bias but research trials don’t (and how that affects results); why everyone needs to place higher importance on the biopsychosocial model; the idea of being more humble with science and using “theoretical” more often; the problems with microdosing trials; and the issues with evidence: If there isn’t sufficient evidence, why isn’t there? And what exactly would be sufficient? www.psychedelicstoday.com

In this episode, Joe interviews Dr. Devon Christie: Senior Lead of Psychedelic Programs at Numinus, educator at CIIS and Vital, and MAPS-certified MDMA therapist; and Dr. Pamela Kryskow, MD: founding board member of the Psychedelic Association of Canada and Medical Lead of the nonprofit, Roots To Thrive. Christie and Kryskow recently co-authored one of the first papers looking at MDMA for chronic pain, “MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder,” which came about after they received access to MAPS’ Phase 2 data from a lead-in PTSD study and noticed significant improvements in pain measurements – something the study was not looking for at all. They’re looking into where chronic pain fits within the frameworks of Western medicine and psychedelic-assisted therapy, and discuss the many reasons why MDMA should be tremendously helpful for chronic pain and other conditions that fall under the large umbrella of central sensitivity syndromes and nociplastic pain. They are currently working on a new study following the MAPS protocol that will research MDMA-assisted psychotherapy specifically for people with fibromyalgia, which some believe might be physicalized PTSD. If you’d like to contribute a tax-deductible donation, visit <a href="http://giving.viu.ca" rel="nofollow" target="_blank">giving.viu.ca</a>, select “other” from the dropdown, and type in “MDMA for Fibromyalgia.” They talk about how research trials focus too much on the molecule while ignoring what the patient is saying; how a large percentage of physicians and patients don’t at all like the psychometrics used in measuring data; how physicians regularly use expectancy bias but research trials don’t (and how that affects results); why everyone needs to place higher importance on the biopsychosocial model; the idea of being more humble with science and using “theoretical” more often; the problems with microdosing trials; and the issues with evidence: If there isn’t sufficient evidence, why isn’t there? And what exactly would be sufficient? <a href="http://www.psychedelicstoday.com" rel="nofollow" target="_blank">www.psychedelicstoday.com</a>

PT391 – Dr. Devon Christie & Dr. Pamela Kryskow, MD – MDMA-Assisted Psychotherapy For Fibromyalgia and Other Central Sensitization Syndromes

This is an uncut interview recorded live at the 2022 Wonderland Conference in Miami, FL. Paul F. Austin is joined by renowned mycologist, author and researcher Paul Stamets, along with Pamela Kryskow, M.D., both co-founders of MycoMedica Life Sciences, PBC. They dive into all things microdosing, clinical trials, naturalistic science and patient-driven research, while exploring and honoring the wisdom of indigenous cultures around the world—and even martial arts. Find episode links, summary, and transcript  here. Paul Stamets, speaker, author, mycologist, medical researcher and entrepreneur, is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. He lectures extensively to deepen the understanding and respect for the organisms that literally exist under every footstep taken on this path of life. Paul’s philosophy is that “MycoDiversity is BioSecurity.” He sees the ancient Old Growth forests of the Pacific Northwest as a resource of incalculable value, especially in terms of its fungal genome. A dedicated hiker and explorer, his passion is to preserve and protect as many ancestral strains of mushrooms as possible from these pristine woodlands. His research is considered breakthrough by thought leaders for creating a paradigm shift for helping ecosystems worldwide. Paul is the author of six books (including Mycelium Running: How Mushrooms Can Help Save the World, Growing Gourmet &amp; Medicinal Mushrooms, and Psilocybin Mushrooms of the World). He has discovered and named several new species of psilocybin mushrooms. Dr. Pamela Kryskow is a medical doctor with a strong interest in psychedelic medicine, mental health and chronic pain. She is a founding board member of the Canadian Psychedelic Association. She is also a part of an expert team working to give Canadians access to psilocybin at end of life. Dr Kryskow is actively involved in research related to psilocybin, MDMA, ketamine, mental wellness and neurogenesis. She is a co-investigator on the largest microdosing study, Microdose.me, which is ongoing with 14 000+ enrolled participants. A Clinical Instructor at University of British Columbia and Adjunct Professor at Vancouver Island University, Dr. Kryskow is also the medical lead on the Roots To Thrive Ketamine Assisted Therapy program, which treats healthcare providers with PTSD, depression, anxiety, and addiction. In real life, she loves foraging in the forest, ocean kayaking, growing kale and daydreaming in the hammock. Highlights:  An introduction to Paul and Pam, and their work together in researching the benefits of microdosing psilocybin. Tracking the history of mushroom wisdom and knowledge, from indigenous traditions to scientific research. How the complexity of microdosing demands new research approaches and methodologies. Addressing the disconnect between policy and science. Paul Stamets’ vision of how psychedelics can be integrated in society, and how MycoMedica is working towards it. How new scientific findings on psilocybin and microdosing could influence future legislation. Closing remarks: psychedelics, kindness, and community  Episode Links  MycoMedica Life Sciences, PBC Microdose.me study Paul Stamets’ talk at the 2017 MAPS Psychedelic Science Conference  The roots of ‘Two-Eyed Seeing’ mushroomreferences.com Quantified Citizen App Paul Stamets’ Website Paul Stamets on Instagram Pamela Kryskow, M.D. on LinkedIn  This episode is brought to you by MycroDrops™ Powerful Micro-Elixirs made from Adaptogen and nootropic herbs and mushrooms. Get MOTIVATED, FOCUSED &amp; GROUNDED! Use code THIRDWAVE and take $10 off your first purchase of $30 or more. Visit www.mycrodrops.com. This episode is brought to you by Apollo Neuro, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just use this link.

This is an uncut interview recorded live at the 2022 Wonderland Conference in Miami, FL. Paul F. Austin is joined by renowned mycologist, author and researcher <a href="http://www.paulstamets.com" rel="nofollow" target="_blank">Paul Stamets</a>, along with <a href="https://www.linkedin.com/in/pamela-kryskow-345a6a200/" rel="nofollow" target="_blank">Pamela Kryskow, M.D.</a>, both co-founders of <a href="https://mycomedica.com/" rel="nofollow" target="_blank">MycoMedica Life Sciences, PBC</a>. They dive into all things microdosing, clinical trials, naturalistic science and patient-driven research, while exploring and honoring the wisdom of indigenous cultures around the world—and even martial arts. Find episode links, summary, and transcript <a href="https://thethirdwave.co/podcast/episode-172-paul-stamets-pamela-kryskow-md/" rel="nofollow" target="_blank"> here</a>. <a href="http://www.paulstamets.com" rel="nofollow" target="_blank">Paul Stamets</a>, speaker, author, mycologist, medical researcher and entrepreneur, is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. He lectures extensively to deepen the understanding and respect for the organisms that literally exist under every footstep taken on this path of life. Paul’s philosophy is that “MycoDiversity is BioSecurity.” He sees the ancient Old Growth forests of the Pacific Northwest as a resource of incalculable value, especially in terms of its fungal genome. A dedicated hiker and explorer, his passion is to preserve and protect as many ancestral strains of mushrooms as possible from these pristine woodlands. His research is considered breakthrough by thought leaders for creating a paradigm shift for helping ecosystems worldwide. Paul is the author of six books (including Mycelium Running: How Mushrooms Can Help Save the World, Growing Gourmet &amp; Medicinal Mushrooms, and Psilocybin Mushrooms of the World). He has discovered and named several new species of psilocybin mushrooms. <a href="https://www.linkedin.com/in/pamela-kryskow-345a6a200/" rel="nofollow" target="_blank">Dr. Pamela Kryskow</a> is a medical doctor with a strong interest in psychedelic medicine, mental health and chronic pain. She is a founding board member of the Canadian Psychedelic Association. She is also a part of an expert team working to give Canadians access to psilocybin at end of life. Dr Kryskow is actively involved in research related to psilocybin, MDMA, ketamine, mental wellness and neurogenesis. She is a co-investigator on the largest microdosing study, <a href="https://microdose.me/" rel="nofollow" target="_blank">Microdose.me</a>, which is ongoing with 14 000+ enrolled participants. A Clinical Instructor at University of British Columbia and Adjunct Professor at Vancouver Island University, Dr. Kryskow is also the medical lead on the Roots To Thrive Ketamine Assisted Therapy program, which treats healthcare providers with PTSD, depression, anxiety, and addiction. In real life, she loves foraging in the forest, ocean kayaking, growing kale and daydreaming in the hammock. Highlights: <ul> <li>An introduction to Paul and Pam, and their work together in researching the benefits of microdosing psilocybin.</li> <li>Tracking the history of mushroom wisdom and knowledge, from indigenous traditions to scientific research.</li> <li>How the complexity of microdosing demands new research approaches and methodologies.</li> <li>Addressing the disconnect between policy and science.</li> <li>Paul Stamets’ vision of how psychedelics can be integrated in society, and how MycoMedica is working towards it.</li> <li>How new scientific findings on psilocybin and microdosing could influence future legislation.</li> <li>Closing remarks: psychedelics, kindness, and community</li> </ul> Episode Links <ul> <li><a href="https://mycomedica.com/" rel="nofollow" target="_blank">MycoMedica Life Sciences, PBC</a></li> <li><a href="https://microdose.me/" rel="nofollow" target="_blank">Microdose.me study</a></li> <li><a href="https://www.youtube.com/watch?v=vFWxWq0Fv0U" rel="nofollow" target="_blank">Paul Stamets’ talk at the 2017 MAPS Psychedelic Science Conference</a></li> <li><a href="https://www.cbc.ca/news/canada/nova-scotia/two-eyed-seeing-doc-1.6304574" rel="nofollow" target="_blank"> The roots of ‘Two-Eyed Seeing’</a></li> <li><a href="https://mushroomreferences.com/" rel="nofollow" target="_blank">mushroomreferences.com</a></li> <li><a href="https://www.quantifiedcitizen.com/" rel="nofollow" target="_blank">Quantified Citizen App</a></li> <li><a href="https://www.paulstamets.com/" rel="nofollow" target="_blank">Paul Stamets’ Website</a></li> <li><a href="https://www.instagram.com/paulstamets/" rel="nofollow" target="_blank">Paul Stamets on Instagram</a></li> <li><a href="https://www.linkedin.com/in/pamela-kryskow-345a6a200/" rel="nofollow" target="_blank">Pamela Kryskow, M.D. on LinkedIn</a></li> </ul> This episode is brought to you by <a href="https://www.mycrodrops.com/discount/THIRDWAVE" rel="nofollow" target="_blank">MycroDrops™</a> Powerful Micro-Elixirs made from Adaptogen and nootropic herbs and mushrooms. Get MOTIVATED, FOCUSED &amp; GROUNDED! Use code <a href="https://www.mycrodrops.com/discount/THIRDWAVE" rel="nofollow" target="_blank">THIRDWAVE</a> and take $10 off your first purchase of $30 or more. Visit <a href="https://www.mycrodrops.com/discount/THIRDWAVE" rel="nofollow" target="_blank">www.mycrodrops.com</a>. This episode is brought to you by <a href="http://apolloneuro.com/thirdwave" rel="noopener nofollow" target="_blank">Apollo Neuro</a>, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just <a href="https://apolloneuro.com/thirdwave" rel="noopener nofollow" target="_blank">use this link</a>.